Fluoroquinolone Can Be an Effective Treatment Option for Acute Pyelonephritis When the Minimum Inhibitory Concentration of Levofloxacin for the Causative Escherichia coli Is ≤16 mg/L

• Published in: Antibiotics (Basel) 2021-01, Vol.10 (1), p.37
• Main Authors: Kim, Yeonjae, Kim, Bongyoung, Wie, Seong Heon, Kim, Jieun, Ki, Moran, Cho, Yong Kyun, Lim, Seung Kwan, Lee, Jin Seo, Kwon, Ki Tae, Lee, Hyuck, Cheong, Hee Jin, Park, Dae Won, Ryu, Seong Yeol, Chung, Moon Hyun, Pai, Hyunjoo
• Format: Article
• Language: English
• Subjects: Antibiotics; Antimicrobial agents; Bacterial infections; Blood; Brief Report; Ciprofloxacin; Clinical outcomes; E coli; Escherichia coli; Fever; fluoroquinolone; Health services; Hospitalization; Laboratories; Levofloxacin; Minimum inhibitory concentration; Mortality; Pathogens; Patients; Pyelonephritis; Response rates; treatment; urinary tract infection; Urinary tract infections; Urine; Womens health
• ISSN: 2079-6382; 2079-6382
• DOI: 10.3390/antibiotics10010037

The purpose of this study was to determine whether the fluoroquinolone (FQ) minimum inhibitory concentration (MIC) for the causative agent influences the clinical response of FQ treatment at 72 h in patients with community-acquired acute pyelonephritis (CA-APN). We prospectively collected the clinical data of women with CA-APN from 11 university hospitals from March 2010 to February 2012 as well as isolates from the urine or blood. In total, 78 patients included in this study received FQ during the initial 72 h, and the causative was detected. The clinical response at 72 h was significantly higher in patients with a levofloxacin MIC ≤ 16 mg/L than in those with an MIC > 16 mg/L (70.4% vs. 28.6%, = 0.038). No difference was observed in clinical response at 72 h based on ciprofloxacin MIC. To summarize, FQ can be an effective treatment option for CA-APN when levofloxacin MIC against is ≤16 mg/L.